text/Yangcheng Evening News all-media reporter Ding Ling Daimanman Sun Jing Xu Zhangchao/Yangcheng Evening News all-media reporter Xu Zhangchao
at the Guangzhou Langsheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Langsheng Yao") located in Science City, Huangpu District, Guangzhou City In the production workshop of "Industry"), various production and R&D equipment are operating flexibly. In addition, in order to meet the needs of the company's business expansion, a new production base with a total investment of 1.3 billion yuan is also under construction.
As a high-tech pharmaceutical company focusing on the research, development, production and sales of reproductive health drugs, chronic disease drugs, and external drugs , in the 21 years since its establishment, Langsheng Pharmaceutical has completed the process of producing only a single product at the beginning to now having a comprehensive range of products in various fields. It has blossomed in transformation, and has more than 30 innovative drugs and medical devices in different stages of research and development in the fields of family planning, perinatal , ED, etc., and was awarded the title of "Guangzhou Specialized New Enterprise" in 2021. At the same time, the company's revenue has entered a stage of rapid and steady growth in the past three years.
"Whether it is daily operations or the expansion of supporting resources such as production bases, the credit funds from ICBC cannot be ignored in helping the company's development." Ma Zhao, financial director of Langsheng Pharmaceutical, was deeply touched by this.
Finding financial partners is a big deal
"As a pharmaceutical company, from product research and development to launch, to sales and production expansion, in the company's development process, in addition to the company's own continuous capital investment, external financial support is also crucial." Zhao Zhirong, general manager of Langsheng Pharmaceutical R&D Center, told the Yangcheng Evening News reporter bluntly.
According to Zhao Zhirong, although at the beginning of its establishment, the company was mainly committed to researching levonorgestrel enteric-coated tablets emergency contraceptive pills and building the first steroid hormone modern production line, the company also realized that it needed To realize the vision of long-term sustainable development, it is not enough to just produce a single product. It is necessary to continuously improve its own R&D strength, increase R&D investment, and enrich the company's product line.
Today, Langsheng Pharmaceutical has a modern laboratory and test workshop covering an area of more than 6,000 square meters, as well as a commercial batch-scale multi-preparation production workshop that complies with GMP, realizing the full process transfer from R&D to production, and successfully creating Danmei Zuo Norgestrel enteric-coated tablets, Red Deer hyaluronic acid condoms, Red Deer sildenafil, tadalafil and other leading products. Among them, Danmei levonorgestrel enteric-coated tablets, as the world's first emergency contraceptive using enteric-coated technology, reduce the vomiting rate and increase the safety and effectiveness of contraception, and won the 21st China Patent Excellence Award.
"As a long-life-cycle product, a drug often takes three to five years or even more than ten years from research and development to its final successful launch, and the purchase of land and buildings, the purchase of R&D and production equipment, and the investment of R&D personnel are often prerequisites. All these have put forward high demands on the company’s capital flow.” Zhao Zhirong also told reporters: “In the process of the early development of products, the existing production plants are no longer enough. If we don’t build a new production base, it will be impossible. Faced with the situation that the production capacity cannot keep up and the products are not sold enough, the company is facing a large financial gap due to the continuous iteration of products and the plan to build a raw material production base, and is in urgent need of external financial support.” Become the top priority for the company's development.
ICBC credit funds came as a "timely rain"
Ma Zhao said: "As the company's capital needs increase for its plans to expand production capacity and build new production bases, it needs to supplement working capital. The company communicated with some banks. In the end, ICBC After researching the company's existing products and patented technologies, they recognized Langsheng Pharmaceutical as a high-quality high-tech enterprise and were very supportive of the company. They provided our company with a technology-based loan with a very favorable interest rate, which helped us a lot," said Ma Zhao. He told a reporter from the Yangcheng Evening News that as of May this year, the company had received a full amount of technology loans from the Industrial and Commercial Bank of China. At the same time, new project loan credits will accelerate the construction progress of the company's new production base.
In addition to providing financial support, ICBC also helps the company sort out its business lines and development ideas. For example, in the preliminary research, it will analyze and communicate based on the company's sales scale, net profit, competitors, etc., and provide macroeconomic information. The latest information including interpretation of economic policies. “These all make us feel that ICBC’s preliminary research and follow-up services are very professional,” said Ma Zhao.
In addition, according to Ma Zhao, ICBC also intends to participate in the company's long-term development. Its investment fund has signed a cooperation framework agreement with the company and will choose the right time to intervene.
has launched 8 exclusive financial products
In fact, Langsheng Pharmaceutical is just one of the cases where ICBC supports specialized and new enterprises.
According to the relevant person in charge of ICBC, in response to Guangzhou’s call to build a national innovation center city and an international science and technology innovation hub, ICBC established a specialized financial service institution for science and technology innovation enterprises in Guangzhou - "Guangzhou Science and Technology Innovation Enterprise Financial Services" Center" and "Guangzhou Science and Technology Branch". Among them, the ICBC Guangzhou Science and Technology Innovation Center is responsible for the overall management of the investment and financing business of science and technology innovation enterprises in Guangzhou; the ICBC Guangzhou Science and Technology Branch is a specialty business branch that provides exclusive implementation services for the investment and loan linkage business of science and technology innovation enterprises.
Since its establishment, ICBC has launched 8 exclusive financial products in Guangzhou, including "Technology Pool Loan", "Technology Innovation High-tech Loan", "ICBC Listed Loan" and "Technology Innovation Loan". By actively collecting market demand and actively Carry out business model innovation, build an investment and loan alliance ecosystem, etc. to support the development of regional science and technology enterprises. In the past three years, it has provided financing support of over RMB 100 billion for companies listed or to be listed in Guangzhou, and continues to inject financial vitality into scientific and technological enterprises. (For more news and information, please follow Yangcheng Pai pai.ycwb.com)
Source | Yangcheng Evening News·Yangcheng Pai
Editor | Hang Ying
